Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NewH2 is the corporate venture capital arm of H&H Group, a global leader in premium health and wellness known for brands such as Swisse and Biostime. The firm focuses on investing in and partnering with high-growth, innovative startups in the fields of health, nutrition, and wellness technology. NewH2 specifically targets early-stage companies that align with H&H Group's core pillars, including pediatric nutrition, adult supplements, and pet wellness. By providing capital and strategic support, NewH2 aims to foster breakthroughs in the microbiome, personalized nutrition, and digital health sectors. The entity serves as a strategic innovation hub, identifying disruptive technologies that can be integrated into the broader H&H ecosystem to enhance consumer health outcomes.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on NewH2.